Clinical Trial

Trial Protocol ID USOR 24106_CC-220-MM-002

Trial Description

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Mohit Narang, MD

Sponsors

  • BRISTOL-MYERS SQUIBB
  • CELGENE

ClinicalTrials.gov NCT ID

  • NCT04975997